Our Research Priorities
Drive Strategic Investments
June 23, 2017
Researchers have developed a tool to predict cognitive decline in PD for use in designing clinical studies. The team analyzed data from multiple studies including PPMI.
June 22, 2017
MJFF-funded researchers published on a connection between the key Parkinson's protein alpha-synuclein and the immune system. This finding may point to a new way to stop or slow disease.
UPCOMING FUNDING PROGRAM DEADLINES
Deadline: Pre-Proposals Due: October 19, 2016 - 5pm US ET
Part of our Edmond J. Safra Core Programs for PD Research, the Therapeutic Pipeline Program supports Parkinson's disease therapeutic development along the pre-clinical and clinical path (both drug and non-pharmacological therapeutics, including gene therapy, biological, surgical and non-invasive approaches).
Deadline: We are no longer accepting pre-proposals at this time.
Part of our Edmond J. Safra Core Programs for PD Research, the Target Advancement program seeks to build robust evidence to rationalize biological pathways and targets for further translation into new Parkinson's treatments.